Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus

BACKGROUND: Only eight women out of one hundred diagnosed with ovarian epithelial cancers, which progressed to the clinical stage IV, survive 10 years. First line therapies: surgery, chemotherapy, and radiation therapy inflict very serious iatrogenic consequences. Passive immunotherapy of ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Malecki, Marek, Putzer, Emily, Quach, Caroline, Dodivenaka, Chaitanya, Tombokan, Xenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130937/
https://www.ncbi.nlm.nih.gov/pubmed/27905089
http://dx.doi.org/10.1186/s40169-016-0125-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130937/
https://www.ncbi.nlm.nih.gov/pubmed/27905089
http://dx.doi.org/10.1186/s40169-016-0125-2

Ejemplares similares